MedTrace Logo

Implications for Management of PET Amyloid Classification Technology

NCT02778971 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2023-04-24

No results posted yet for this study

Summary

The main purpose of this study is to explore the impact of an amyloid positron emission tomography and computed tomography (PET/CT) scan on physician diagnosis and management, including drug management and care practices, for patients with a diagnosis of cognitive impairment. This study also intends to capture specific patient-reported outcomes related to patient burden, confidence and satisfaction.

The hypothesis is that to aid early diagnosis, individuals with a diagnostically uncertain etiology for their dementia will benefit from knowledge of amyloid plaque burden status, through an alteration of patient diagnosis and management, which will lead to significant changes in patient and care partner reported outcomes.

Conditions

Interventions

DRUG

[18F]Flutemetamol

amyloid PET imaging with \[18F\]Flutemetamol and subsequent modification of diagnosis and management

Sponsors & Collaborators

Principal Investigators

  • Norman L. Foster, M.D. · Director: Center for Alzheimer's Care, Imaging & Research; Chief: Division of Cognitive Neurology; Senior Investigator: The Brain Institute; Professor: Dept. of Neurology University of Utah School of Medicine

  • John M. Hoffman, M.D. · Professor of Radiology and Neurology Director of Nuclear Medicine; Director: Center for Quantitative Cancer Imaging Huntsman Cancer Institute University of Utah School of Medicine

Eligibility

Min Age
45 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-06-30
Completion
2022-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02778971 on ClinicalTrials.gov